小板凳社区收集 xiaobandeng. com comparative analysis of promoter consensus search, run-off transcription/macroarray analysis(ROMA), and transcriptional profiling approaches. J Mol BioL, 2001, 313(4): 903-19 (2) Markstein M, Markstein P, Markstein V, et al. Genome-wide analysis of clustered dorsal binding sites identifies putative target genes in the Drosophila embryo. Pro Natl Acad Sci UsA,2002,99(2):763-8 (3)Kloos DU, Choi C, Wingenderf E The TGF-beta- Smad network: introducing bioinformatics tools. Trends Genet, 2002, 18(2): 96-103 (4)Read TD, Gill SR, Tettelin H, et al. Finding drug targets in microbial genomes. Drug Discov Today,2001,6(17):887-892 (5)Innocenti F, Ratain MJ. Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer, 2002,38(5)639-6 (6) Werner T. Cluster analysi promoter modeling as bioinformatics tools for the indentification of target from expression array data. Pharmacogenomics, 1,2(1)25-36 (7) Tornell J, Snaith M. Transgenic systems in drug discovery: from target identification to humanized mice. Drug Discov Today, 2002, 7(8): 461-470 (8)Gachet C ADP receptors of platelets and their inhibition. Thromb Haemost 2001 86(1): 222-3 (9)Rosen LS. Clinical experience with angiogenis signaling inhibitors: focus on vascular endothelial growth factor(VEGF) blockers. Cancer ControL, 2002, 9(2 Suppl): 36-44 (10)Lai J, Gold MS, Kim CS, et al. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1. 8. Pain, 2002, 95(1-2): 143-52 (11)Croston GE. Functional cell-based uHTS in chemical genomic drug discovery. Trends Biotechnol,2002,20(3):110-115 interactions: insight into structure-based ligand design.J Med Chem, 2002, 45(7): 1412-0or (12)Huo S, Wang J, Cieplak P, et al. Dynamics and free energy analyses of cathepsin D-inhibi (13)Pattabiraman N. Analysis of ligand-macromolecule contacts: computational methods. Curr Med chen,2002,9(5)609-621 (14) Hirono S. An introduction to the computer-aided structure-based drug design-applications of bioinformatics to drug discovery. Rinsho Byori, 2002 50(1): 45-51 (15) Dahl SG Edvardsen O, Kristiansen K, et al. Bioinformatics and receptor mechanisms of drugs. Biotechnol Annu Rev. 2001, 7: 165-177 (16) Rothberg BEG The use of animal models in expression pharmacogenomic analyses Pharmacogenomics J, 2001, 1(1): 48-5 (17)Bugelski PJ. Gene expression profiling for pharmaceutical toxicology screening. Curr Opin Drug Discov Devel, 2002, 5(1): 79-89 (18)Los G Yang F, Samimi G, et al. Using mRNA expression profiling to determine anticancer drug efficancy. Cytometry, 2002, 47(1): 66-71 (19)Zembutsu H, Ohnishi Y, Tsunoda T, et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res, 2002, 62(2): 518-27 (20)Raucy J L, Allen S W. Recent advances in P450 research. Pharmacogenomics J 200 lIssue 3: 178-86 (21)Adam Gl. The development of pharmacogenomic models to predict drug response. Curr Opin Drug Discov Devel, 2001, 4(3): 296-300 (22)Chen X, Ji ZL, Chen YZ. TTD: therapeutic target database. Nucleic Acids Res, 2002,30(1)412-5 三、总体目标、五年目标 1.总体目标小板凳社区收集 xiaobandeng.com comparative analysis of promoter consensus search., run-off transcription/macroarray analysis(ROMA), and transcriptional profiling approaches. J Mol Biol, 2001,313(4):903-19 (2) Markstein M, Markstein P, Markstein V, et al. Genome-wide analysis of clustered dorsal binding sites identifies putative target genes in the Drosophila embryo. Pro Natl Acad Sci USA, 2002,99(2):763-8 (3) Kloos DU, Choi C, Wingenderf E. The TGF-beta- Smad network: introducing bioinformatics tools.Trends Genet, 2002,18(2):96-103 (4) Read TD, Gill SR, Tettelin H,et al. Finding drug targets in microbial genomes. Drug Discov Today，2001，6（17）：887-892 (5) Innocenti F, Ratain MJ. Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer, 2002, 38(5):639-644 (6) Werner T. Cluster analysis and promoter modeling as bioinformatics tools for the indentification of target genes from expression array data. Pharmacogenomics, 2001,2(1):25-36 (7) Tornell J, Snaith M. Transgenic systems in drug discovery: from target identification to humanized mice. Drug Discov Today,2002, 7(8):461-470 (8) Gachet C.ADP receptors of platelets and their inhibition.Thromb Haemost 2001 86 (1):222-3 (9) Rosen LS. Clinical experience with angiogenis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control,2002, 9( 2 Suppl):36-44 (10) Lai J, Gold MS, Kim CS, et al. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain, 2002, 95(1-2):143-52 (11) Croston GE. Functional cell-based uHTS in chemical genomic drug discovery. Trends Biotechnol, 2002,20(3):110-115 (12) Huo S, Wang J, Cieplak P, et al. Dynamics and free energy analyses of cathepsin D-inhibitor interactions: insight into structure-based ligand design.J Med Chem, 2002 ,45(7):1412-9 (13) Pattabiraman N. Analysis of ligand-macromolecule contacts: computational methods. Curr Med Chem, 2002,9(5):609-621 (14) Hirono S. An introduction to the computer-aided structure-based drug design-applications of bioinformatics to drug discovery. Rinsho Byori, 2002,50(1):45-51 (15) Dahl SG, Edvardsen O, Kristiansen K, et al. Bioinformatics and receptor mechanisms of psychotropic drugs. Biotechnol Annu Rev, 2001,7:165-177 (16) Rothberg BEG. The use of animal models in expression pharmacogenomic analyses. Pharmacogenomics J,2001,1(1):48-58 (17) Bugelski PJ. Gene expression profiling for pharmaceutical toxicology screening. Curr Opin Drug Discov Devel, 2002, 5(1):79-89 (18) Los G, Yang F, Samimi G, et al. Using mRNA expression profiling to determine anticancer drug efficancy. Cytometry,2002, 47(1):66-71 (19) Zembutsu H, Ohnishi Y, Tsunoda T, et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res, 2002, 62(2):518-27 (20) Raucy J L, Allen S W. Recent advances in P450 research.Pharmacogenomics J 2001 1Issue 3:178-86 (21) Adam GI. The development of pharmacogenomic models to predict drug response. Curr Opin Drug Discov Devel, 2001, 4(3):296-300 (22) Chen X, Ji ZL, Chen YZ. TTD: therapeutic target database. Nucleic Acids Res, 2002,30(1):412-5 三、总体目标、五年目标 1．总体目标 9